Table 3. Tissue Expression of FasL Immune Staining in Liver Tissue of Different Studied Cases.
| Histopathologic Diagnosis, No. | Positive Cases, No. (%) | Range, No. | Intensity, % | ||||
|---|---|---|---|---|---|---|---|
| < 10% | 10% - 50% | > 50% | + | + + | + + + | ||
| Controls, 10 | 0 (0) | - | - | - | - | - | - |
| CHC without cirrhosis, 30 | 13 (43.3) a | 3 | 10 | - | 8 | 5 | - |
| CHC with cirrhosis, 30 | 17 (56.6) a, b | 6 | 6 | 5 | 4 | 8 | 5 |
| HCC, 30 | 16 (53.3) a, c | 2 | 7 | 7 | - | 7 | 9 |
Abbreviations: CHC, chronic hepatitis C; HCC, hepatocellular carcinoma.
aP < 0.01 significant difference relative to control group.
bP < 0.05 significant difference relative to CHC without cirrhosis.
cP < 0.05 significant difference relative to CHC with cirrhosis.